

Date and time: Monday 30 March 2015, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting **Diagnosis and monitoring of asthma**
14

Place: **Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ**

Present: John Alexander, Consultant in Paediatrics & Paediatric Intensive Care
Tara Burn, Patient member
Erol Gaillard, Senior Lecturer & Honorary Consultant in Paediatric
Respiratory Medicine
Val Hudson, Patient member
Ren Lawlor, Respiratory Nurse Specialist & Senior Lecturer in Adult
Nursing
Matthew Masoli, Consultant Respiratory Physician
Melanie McFeeters, Consultant Nurse in Children’s Respiratory
Diseases & Quality Lead for Specialised Commissioning (East
Midlands) (secondment position to NHS England)
Andrew Menzies-Gow (Chair), Consultant in Respiratory Medicine
Michael Thomas, Professor of Primary Care Research (MT did not
formally participate for the discussion on FeNO in items 3-4)
Emily Davies, Senior Research Fellow, NCGC
Alex Haines, Senior Health Economist, NCGC
Bernard Higgins, Clinical Director, NCGC
Emma Madden, Research Fellow, NCGC
Amelia Unsworth, Project Manager, NCGC (notes)

Apologies: Angela Key, Chief Respiratory Physiologist
Georgina Russell, RCP Clinical Fellow (Specialist Trainee Adviser)
Tahmina Siddiqui, General Practitioner partner

In attendance:

NICE Staff: NICE attendee 1	Gareth Haman, Senior Medical Editor	
NICE attendee 2	Caroline Keir , Guidelines Commissioning Manager	
NICE attendee 3	Adam Storrow, Costings Analyst	
NICE attendee 4	Katie Wyart, Implementation Adviser (item 5 onwards)	

Observers:

--	--	--

Notes

1. **Welcome and declarations of interest**

The Chair welcomed the group to the fourteenth meeting of this GDG. Apologies were received from AK, GR and TS.

The Chair reviewed the declarations of interest register and noted that, due to previously declared specific non-personal pecuniary interests, MT has a conflict of interest with FeNO and did not formally participate in the discussions on FeNO but remained present to answer direct questions of fact on the Chair's request.

The Chair requested updates to the GDG members' existing DOIs. AMG declared that he received speaker fees from GlaxoSmithKline, Novartis, AstraZeneca and Boehringer Ingelheim for speaking about new treatment options for asthma. AMG also attended an advisory board for Roche discussing novel therapies for severe asthma. These DOIs were classified as non-specific personal pecuniary interests. The guideline lead agreed that no action was required. No other new declarations of interest were received and therefore no action was required.

2. **GDG13 minutes**

The minutes of the last meeting were agreed as a true and accurate record.

3. **Stakeholder comments**

MT did not formally participate for the discussion on FeNO. The GDG discussed and agreed changes to the draft recommendations in light of stakeholder comments and agreed draft responses.

4. **Diagnostic algorithm for children 5-16 years**

MT did not formally participate for the discussion on FeNO. The GDG discussed and agreed changes to the draft diagnostic algorithm for children aged 5-16 years.

5. **Implementation plans**

The GDG was given a presentation on the implementation plans.

6. **Key priorities for implementation**

The GDG reviewed and agreed changes to the key priorities for implementation.

7. **Research recommendations**

The GDG reviewed the research recommendations.

8. **Any other business**

None.

Date, time and venue of the next meeting

None – this is the last meeting of this GDG.